Skip to main content

Table 4 Biologic therapeutics in use or in development for use in juvenile idiopathic arthritis (JIA)

From: Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis

Drug Target FDA approval for JIA Route Dosage options
Etanercept
(Enbrel)
TNFα Polyarticular JIA ages 2 years and older Subcutaneous injection 0.8 mg/kg/dose once a week, maximum 50 mg/dose
Infliximab
(Remicade)
TNFα No Intravenous infusion 6 to 10 mg/kg/dose weeks 0, 2 and 6; then every 4 to 8 weeks
Adalimumab
(Humira)
TNFα Polyarticular JIA ages 4 years and older Subcutaneous injection 24 mg/m2 every 2 weeks, maximum 40 mg/dose
Anakinra
(Kineret)
IL-1 No Subcutaneous injection 1 to 2 mg/kg/day, maximum 100 mg/dose
Rilonacept
(IL-1 Trap)
IL-1 No Subcutaneous injection 2.2 to 4.4 mg/kg once a week
Abatacept
(Orencia)
Cytotoxic T-lymphocyte- associated antigen 4 Polyarticular JIA ages 6 years and older Intravenous infusion 10 mg/kg weeks 0, 2 and 4; then every 4 weeks, maximum 1,000 mg/dose
Rituximab
(Rituxan)
CD20 No Intravenous infusion 750 mg/m2; two doses 2 weeks apart or 375 mg/m2; four doses, weekly × 4, maximum 1,000 mg/dose
Tocilizumab
(MRA)
IL-6 No Intravenous infusion 8 to 12 mg/kg every 2 weeks
  1. FDA, Food and Drug Administration.